Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986556 · ClinicalTrials.gov registry record · Phase 1
Lesinurad Tablet Relative Bioavailability
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01986556: Completed Phase 1 study, sponsored by Ardea Biosciences.
NCT01986556 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01986556, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will assess the relative bioavailability of lesinurad tablets, manufactured at two different sites.
Primary Outcome
PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); and apparent terminal half-life (t1/2).
Interventions
- DRUG Lesinurad 400 mg (Site 1)
- DRUG Lesinurad 400 mg (Site 2, Lot A)
- DRUG Lesinurad 400 mg (Site 2, Lot B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01986556 record still lists
NCT01986556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 3 interventions - of which Lesinurad 400 mg (Site 1) is the first listed.
NCT01986556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01986556 about?
NCT01986556 is a clinical study titled "Lesinurad Tablet Relative Bioavailability". This study will assess the relative bioavailability of lesinurad tablets, manufactured at two different sites.
What is the current status of trial NCT01986556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-11. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01986556?
The interventions under investigation include: Lesinurad 400 mg (Site 1) (DRUG), Lesinurad 400 mg (Site 2, Lot A) (DRUG), Lesinurad 400 mg (Site 2, Lot B) (DRUG).
Who is sponsoring clinical trial NCT01986556?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01986556's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia